Heart Failure with Hyperuricemia Dotinurad, Heart Failure, Hyperuricemia, eGFR
Conditions
Interventions
Administer one tablet of the drug Dochinurad 0.5 mg once daily after breakfast. In the 4th week, increase the dosage to 1.0 mg once daily after breakfast. In the 8th week, further increase the dosage
Sponsors
Mizoguchi Tatsuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) At least 18 years old at the time of obtaining consent (2) Diagnosed hyperuricemia with a serum uric acid level (sUA) greater than 7.0 mg/dL (3) eGFR greater than 30 mL/min/1.73m2 and less than 60 mL/min/1.73m2 (4) Verifiable eGFR values measured in the year (plus minus 2 months) before the date of enrollment (5) A confirmed diagnosis of symptomatic chronic heart failure at the time of inclusion, meeting all of the following criteria (a) NT-proBNP greater than 125 pg/mL or BNP greater than 35 pg/mL (b)Typical symptoms and signs of heart failure for at least 6 weeks before enrollment (c)If you are using sodium-glucose co-transporter 2 (SGLT2) inhibitors, they should have been used for at least 6 months before obtaining consent; if using sacubitril/valsartan, it should have been used for at least 4 weeks before receiving permission, and at a stable dose (6) Patients who can obtain written consent based on the free will of the research subject
Exclusion criteria
Exclusion criteria: (1)Patients with active gout attacks (2)Patients with AST or ALT > 100 IU/L (3)Patients with a diagnosis of secondary hyperuricemia (4)Patients with a history of hypersensitivity to dotinurad (5)Patients with a diagnosis of urinary tract stones (6) Pregnant or breastfeeding patients for whom switching to formula is difficult. (7)Other patients deemed by the principal investigator/associate investigator to be ineligible for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of eGFR slope (mL/min/1.73m2/year) before and after Dotinurad administration | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of NT-proBNP before and after Dotinurad administration The change of 6 minutes walk distances before and after Dotinurad administration The change of KCCQ-QS before and after Dotinurad administration The change of the parameters of echocardiography such as left ventricular ejection fraction, left ventricular outflow tract verocity time integral and trans mitral flow before and after Dotinurad administration | — |
Contacts
Public ContactTatsuya Mizoguchi
Nagoya City University Hospital
Outcome results
None listed